EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial

Virchows Archiv

Volumn 471, Issue 4, 2017, Pages 509-520

  Fassunke, Jana ^a   Ihle, Michaela Angelika ^a   Lenze, Dido ^b   Lehmann, Annika ^b   Hummel, Michael ^b   Vollbrecht, Claudia ^b   Penzel, Roland ^c   Volckmar, Anna Lena ^c   Stenzinger, Albrecht ^c   Endris, Volker ^c   Jung, Andreas ^d   Lehmann, Ulrich ^e   Zeugner, Silke ^f   Baretton, Gustavo ^f   Kreipe, Hans ^e   Schirmacher, Peter ^c   Kirchner, Thomas ^d   Dietel, Manfred ^b   Büttner, Reinhard ^a   Merkelbach Bruse, Sabine ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Blood and plasma samples; DNA sequencing; EGFR; FFPE; Liquid biopsy; NSCLC; Osimertinib; T790M mutation; Tumor tissue

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; CIRCULATING TUMOR DNA; EGFR PROTEIN, HUMAN;

ARTICLE; BLOOD SAMPLING; CELL FREE SYSTEM; CONTROLLED STUDY; DNA SEQUENCE; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIQUID BIOPSY; MOLECULAR DIAGNOSTICS; MUTATIONAL ANALYSIS; NON SMALL CELL LUNG CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PYROSEQUENCING; QUALITY CONTROL; SANGER SEQUENCING; BLOOD; CLINICAL TRIAL; DNA MUTATIONAL ANALYSIS; GENETICS; GENOTYPING TECHNIQUE; GERMANY; HEALTH CARE QUALITY; LUNG TUMOR; STANDARDS;

CARCINOMA, NON-SMALL-CELL LUNG; CIRCULATING TUMOR DNA; DNA MUTATIONAL ANALYSIS; GENOTYPING TECHNIQUES; GERMANY; HUMANS; LUNG NEOPLASMS; QUALITY ASSURANCE, HEALTH CARE; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 85029008398     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-017-2226-8     Document Type: Article

References (44)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30
2. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139
3. Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (New York, NY) 304:1497–1500
4. Ellison G, Zhu G, Moulis A, Dearden S, Speake G, McCormack R (2013) EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol 66:79–89
5. Szumera-Cieckiewicz A, Olszewski WT, Tysarowski A et al (2013) EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence. Int J Clin Exp Pathol 6:2800–2812
6. Pao W, Miller V, Zakowski M et al (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306–13311
7. Choughule A, Noronha V, Joshi A et al (2013) Epidermal growth factor receptor mutation subtypes and geographical distribution among Indian non-small cell lung cancer patients. Indian J Cancer 50:107–111
8. Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121–128
9. Park K, Tan EH, O'Byrne K et al (2016) Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol 17:577–589
10. D'Angelo SP, Pietanza MC, Johnson ML et al (2011) Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol 29:2066–2070
11. Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957
12. Fenizia F, De Luca A, Pasquale R et al (2015) EGFR mutations in lung cancer: from tissue testing to liquid biopsy. Future Oncol (London, England) 11:1611–1623
13. Chouaid C, Dujon C, Do P et al (2014) Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12–01). Lung Cancer (Amsterdam, Netherlands) 86:170–173
14. Mellert H, Foreman T, Jackson L et al (2017) Development and clinical utility of a blood-based test service for the rapid identification of actionable mutations in non-small cell lung carcinoma. J Mol Diagn 19:404–416
15. Ionescu DN (2013) Impact of the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology clinical practice guidelines for EGFR and ALK testing in lung cancer in Canada. Curr Oncol (Toronto, Ont) 20:220–226
16. Oxnard GR, Thress KS, Alden RS et al (2016) Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol 34:3375–3382
17. Zhou C, Wu YL, Chen G et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12:735–742
18. Sequist LV, Waltman BA, Dias-Santagata D et al (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3:75ra26
19. Kobayashi S, Boggon TJ, Dayaram T et al (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786–792
20. Pao W, Miller VA, Politi KA et al (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73
21. Yu HA, Arcila ME, Rekhtman N et al (2013) Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 19:2240–2247
22. Balak MN, Gong Y, Riely GJ et al (2006) Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12:6494–6501
23. FDA (2016) Osimertinib Journal. https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm549683.htm
24. EMA (2016) Osimertinib. Journal. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004124/human_med_001961.jsp&mid=WC0b01ac058001d124
25. Cross DA, Ashton SE, Ghiorghiu S et al (2014) AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 4:1046–1061
26. Janne PA, Yang JC, Kim DW et al (2015) AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372:1689–1699
27. Ramalingam S, Yang JC, Lee CK et al (2016) LBA1_PR: osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two phase I expansion cohorts. J Thorac Oncol 11:S152
28. Kurman RJCM, Herrington CS, Young RH (2014) WHO classification of tumours, Volume 6, WHO Press ISBN-13 9789283224358
29. Travis WD, Brambilla E, Nicholson AG et al (2015) The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 10:1243–1260
30. Heydt C, Fassunke J, Kunstlinger H et al (2014) Comparison of pre-analytical FFPE sample preparation methods and their impact on massively parallel sequencing in routine diagnostics. PLoS One 9:e104566
31. Konig K, Peifer M, Fassunke J et al (2015) Implementation of amplicon parallel sequencing leads to improvement of diagnosis and therapy of lung cancer patients. J Thorac Oncol 10:1049–1057
32. Landi L, Cappuzzo F (2014) Pharmacotherapy targeting the EGFR oncogene in NSCLC. Expert Opin Pharmacother 15:2293–2305
33. Gil-Bazo I, Rolfo C (2016) AZD9291 in TKI EGFR resistance in non-small cell lung cancer and the new concept of phase I trials. Transl Lung Cancer Res 5:85–88
34. Stewart EL, Tan SZ, Liu G, Tsao MS (2015) Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review. Transl Lung Cancer Res 4:67–81
35. Sun W, Yuan X, Tian Y et al (2015) Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer. J Hematol Oncol 8:95
36. Mack PC, Holland WS, Burich RA et al (2009) EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J Thorac Oncol 4:1466–1472
37. Tsang JC, Lo YM (2007) Circulating nucleic acids in plasma/serum. Pathology 39:197–207
38. Murtaza M, Dawson SJ, Tsui DW et al (2013) Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497:108–112
39. Sholl LM, Aisner DL, Allen TC et al (2016) Liquid biopsy in lung cancer: a perspective from members of the pulmonary pathology society. Arch Pathol Lab Med 140:825–829
40. Yanagita M, Redig AJ, Paweletz CP et al (2016) A prospective evaluation of circulating tumor cells and cell-free DNA in EGFR-mutant non-small cell lung cancer patients treated with erlotinib on a phase II trial. Clin Cancer Res 22:6010–6020
41. Lindeman NI, Cagle PT, Beasley MB et al (2013) Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 137:828–860
42. Naidoo J M, Drilon A (2014) Molecular diagnostic testing in non-small cell lung cancer. Am J Hematol Oncol. Available on http://www.gotoper.com/publications/ajho/2014/2014sep/molecular-diagnostic-testing-in-non-small-cell-lung-cancer. Last accessed October 20, 2016
43. Reck M, Hagiwara K, Han B et al (2016) ctDNA determination of EGFR mutation status in European and Japanese patients with advanced NSCLC: the ASSESS study. J Thorac Oncol 11:1682–1689
44. Zhang XC, Zhang J, Li M et al (2013) Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies. J Transl Med 11:168